Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pollinex Quattro Grass dose-finding study in seasonal allergic rhinoconjunctivitis
2017-000333-31Phase 2Completed
- Sponsor
- Allergy Therapeutics PLC
- Start
- Jun 2017
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Grass MATA MPL in seasonal allergic rhinitis (SAR) and grass pollen allergy (8 arms), sponsored by Allergy Therapeutics PLC. Primary endpoint: Post-treatment total symptom score following conjunctival provocation test. Started Jun 2017; status: completed.
02
Drugs
Grass MATA MPL
03
Conditions
seasonal allergic rhinitis (SAR)grass pollen allergy
Beyond the preview
Go deeper on 2017-000333-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000333-31.